Niclas Stiernholm
Director/Board Member chez Ontario Bioscience Industry Organization
Profil
Niclas Stiernholm currently works at Tarix Pharmaceuticals Ltd., as Director, Ontario Bioscience Industry Organization, as Director, and Vasomune Therapeutics, Inc., as Director.
Dr. Stiernholm also formerly worked at Trillium Therapeutics ULC, as President, Chief Executive Officer & Director from 2013 to 2019, Trillium Therapeutics, Inc., as Chief Executive Officer & Director from 2011 to 2014, AIM Therapeutics, Inc., as Director, Ontario Genomics Institute (Private Equity), as Director, Bristol-Myers Squibb FCT bêta, Inc., as Director, YM BioSciences, Inc., as Chief Scientific Officer & Executive VP in 2002, Allelix Biopharmaceuticals, Inc., as Manager-Business Development in 1999, and Fight Against Cancer Innovation Trust, as Executive In Residence.
Dr. Stiernholm received his undergraduate degree from Elon University and doctorate degree from the University of Toronto.
Postes actifs de Niclas Stiernholm
| Sociétés | Poste | Début |
|---|---|---|
Ontario Bioscience Industry Organization
 Ontario Bioscience Industry Organization Miscellaneous Commercial ServicesCommercial Services The Ontario Bioscience Industry Organization is a membership organization that engages in strategy, programming, policy development, and advocacy. The non-profit company is based in Toronto, Canada. The Canadian company was founded by Simon Goulet. Maura Campbell has been the CEO of the company since 2021. | Director/Board Member | - |
Tarix Pharmaceuticals Ltd.
 Tarix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Tarix Pharmaceuticals Ltd. develops peptide drugs. The private company is based in Brookline, MA. The company was founded by Joerg Gruber, Richard L. Franklin. Richard L. Franklin has been the CEO since incorporation. | Director/Board Member | - |
Vasomune Therapeutics, Inc.
 Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Director/Board Member | - |
Anciens postes connus de Niclas Stiernholm
| Sociétés | Poste | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Chief Executive Officer | 29/04/2019 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Chief Tech/Sci/R&D Officer | 01/10/2002 |
| Allelix Biopharmaceuticals, Inc. | Corporate Officer/Principal | 01/01/1999 |
Fight Against Cancer Innovation Trust
 Fight Against Cancer Innovation Trust Investment ManagersFinance Fight Against Cancer Innovation Trust is a venture capital firm founded in 2014. The firm is headquartered in Toronto, Canada. | Private Equity Investor | - |
Bristol-Myers Squibb FCT bêta, Inc.
 Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Formation de Niclas Stiernholm
| Elon University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
| Allelix Biopharmaceuticals, Inc. | Health Technology |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Tarix Pharmaceuticals Ltd.
Tarix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Tarix Pharmaceuticals Ltd. develops peptide drugs. The private company is based in Brookline, MA. The company was founded by Joerg Gruber, Richard L. Franklin. Richard L. Franklin has been the CEO since incorporation. | Health Technology |
| AIM Therapeutics, Inc. | Health Technology |
Ontario Genomics Institute (Private Equity)
 Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London. | Finance |
Ontario Bioscience Industry Organization
Ontario Bioscience Industry Organization Miscellaneous Commercial ServicesCommercial Services The Ontario Bioscience Industry Organization is a membership organization that engages in strategy, programming, policy development, and advocacy. The non-profit company is based in Toronto, Canada. The Canadian company was founded by Simon Goulet. Maura Campbell has been the CEO of the company since 2021. | Commercial Services |
Fight Against Cancer Innovation Trust
Fight Against Cancer Innovation Trust Investment ManagersFinance Fight Against Cancer Innovation Trust is a venture capital firm founded in 2014. The firm is headquartered in Toronto, Canada. | Finance |
Bristol-Myers Squibb FCT bêta, Inc.
Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada. | Health Technology |
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Vasomune Therapeutics, Inc. operates as an early stage biopharmaceutical company. It develops medicines to harness the body’s ability to defend against illness by modifying cellular response to disease. The company is headquartered in Toronto, Canada. | Health Technology |
